• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FEC100 治疗患者化疗所致恶心和呕吐(CINV)的风险分析。

Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.

机构信息

Breast Center, Dokkyo Medical University, Tochigi, Japan

Department of Medical Informatics, Niigata University, Niigata, Japan.

出版信息

Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596.

DOI:10.21873/anticanres.13596
PMID:31366522
Abstract

BACKGROUND/AIM: Risk factors for chemotherapy-induced nausea and vomiting (CINV) with anthracycline-containing regimen for breast cancer patients remain unknown. The risk factors for CINV with FEC100 were investigated.

PATIENTS AND METHODS

Data on CINV events and patient backgrounds of 180 patients were collected from the first cycle of FEC100 treatment. In this regimen, patients were administered various antiemetics (ADs). The combinations of ADs were classified into four categories, while body mass index (BMI) was stratified into three categories. Risk factors were selected based on patient characteristics and combination of ADs. Risks for CINV were analyzed by univariate and multivariate analyses.

RESULTS

In the univariate analysis of nausea, BMI was a significant factor, while BMI and combination of ADs were significant in vomiting. In the multivariate analysis concerning nausea, BMI was a significant factor. In the analysis concerning vomiting, the combination of ADs and BMI were significant.

CONCLUSION

BMI was the most important risk factor for nausea and vomiting, while the combination of ADs was for vomiting.

摘要

背景/目的:含蒽环类药物的乳腺癌化疗方案引起的恶心和呕吐(CINV)的风险因素尚不清楚。本研究旨在调查 FEC100 方案中 CINV 的风险因素。

方法

收集了 180 例接受 FEC100 治疗的患者的 CINV 事件和患者背景数据。在该方案中,患者使用了不同的止吐药物(ADs)。根据 AD 的组合将其分为四类,并将体重指数(BMI)分为三类。基于患者特征和 AD 的组合选择风险因素。通过单因素和多因素分析评估 CINV 的风险。

结果

在恶心的单因素分析中,BMI 是一个显著的因素,而在呕吐的单因素分析中,BMI 和 AD 的组合是显著的。在关于恶心的多因素分析中,BMI 是一个显著的因素。在关于呕吐的多因素分析中,AD 的组合和 BMI 是显著的。

结论

BMI 是恶心和呕吐最重要的风险因素,而 AD 的组合是呕吐的风险因素。

相似文献

1
Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.FEC100 治疗患者化疗所致恶心和呕吐(CINV)的风险分析。
Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596.
2
Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.含帕洛诺司琼或格拉司琼三联止吐方案预防含顺铂化疗所致恶心呕吐的风险因素:一项随机、双盲对照试验的分析。
Support Care Cancer. 2019 Mar;27(3):1139-1147. doi: 10.1007/s00520-018-4403-y. Epub 2018 Aug 10.
3
Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.预测化疗相关恶心和呕吐的风险因素评估:一项欧洲前瞻性观察性研究的结果
J Pain Symptom Manage. 2014 May;47(5):839-848.e4. doi: 10.1016/j.jpainsymman.2013.06.012. Epub 2013 Sep 24.
4
Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.接受蒽环类药物/环磷酰胺化疗的乳腺癌患者恶心和呕吐的控制
Anticancer Res. 2018 Feb;38(2):877-884. doi: 10.21873/anticanres.12297.
5
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.测试止吐指南的有效性:日本CINV研究组前瞻性登记研究结果
Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15.
6
Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.日本CINV研究组的一项前瞻性登记研究:食管癌患者化疗引起的恶心和呕吐在延迟期控制较差。
Dis Esophagus. 2017 Feb 1;30(2):1-7. doi: 10.1111/dote.12482.
7
Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.190例结直肠癌患者化疗引起的恶心和呕吐:日本化疗引起的恶心和呕吐研究组的一项前瞻性登记研究
Expert Opin Pharmacother. 2017 Jun;18(8):753-758. doi: 10.1080/14656566.2017.1317746. Epub 2017 Apr 21.
8
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.与基于蒽环类化疗的日本乳腺癌患者中帕洛诺司琼、阿瑞匹坦和地塞米松止吐疗效相关的遗传风险因素。
Clin Breast Cancer. 2018 Apr;18(2):e157-e165. doi: 10.1016/j.clbc.2017.05.013. Epub 2017 Jun 29.
9
Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.台湾地区化疗引起的恶心和呕吐发生率:医生和护士的估计与患者报告的结果对比
Support Care Cancer. 2005 May;13(5):277-86. doi: 10.1007/s00520-005-0788-5. Epub 2005 Mar 16.
10
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).化疗引起的恶心和呕吐:持续症状的发生率、特征及未来方向 NCCTG N08C3(联盟)
Support Care Cancer. 2016 Jun;24(6):2661-7. doi: 10.1007/s00520-016-3080-y. Epub 2016 Jan 15.

引用本文的文献

1
Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: Risk Factor and Predictive Model Using Classification and Regression Tree (CART).乳腺癌患者化疗引起的恶心和呕吐:使用分类与回归树(CART)的危险因素及预测模型
Cureus. 2023 Aug 31;15(8):e44438. doi: 10.7759/cureus.44438. eCollection 2023 Aug.
2
Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).转移性结直肠癌患者化疗引起的恶心和呕吐的风险因素:一项前瞻性队列研究(YCOG1301)。
Int J Colorectal Dis. 2020 Dec;35(12):2323-2329. doi: 10.1007/s00384-020-03731-7. Epub 2020 Aug 28.